Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 22

1.

Retrospective analysis of safety and efficacy of anti-PD-1 therapy and radiation therapy in advanced melanoma: A bi-institutional study.

Mowery YM, Patel K, Chowdhary M, Rushing CN, Roy Choudhury K, Lowe JR, Olson AC, Wisdom AJ, Salama JK, Hanks BA, Khan MK, Salama AKS.

Radiother Oncol. 2019 Sep;138:114-120. doi: 10.1016/j.radonc.2019.06.013. Epub 2019 Jun 25.

PMID:
31252292
2.

Phase 1/2 study of epacadostat in combination with ipilimumab in patients with unresectable or metastatic melanoma.

Gibney GT, Hamid O, Lutzky J, Olszanski AJ, Mitchell TC, Gajewski TF, Chmielowski B, Hanks BA, Zhao Y, Newton RC, Maleski J, Leopold L, Weber JS.

J Immunother Cancer. 2019 Mar 20;7(1):80. doi: 10.1186/s40425-019-0562-8.

3.

Durable Tumor Regression and Overall Survival in Patients With Advanced Merkel Cell Carcinoma Receiving Pembrolizumab as First-Line Therapy.

Nghiem P, Bhatia S, Lipson EJ, Sharfman WH, Kudchadkar RR, Brohl AS, Friedlander PA, Daud A, Kluger HM, Reddy SA, Boulmay BC, Riker AI, Burgess MA, Hanks BA, Olencki T, Margolin K, Lundgren LM, Soni A, Ramchurren N, Church C, Park SY, Shinohara MM, Salim B, Taube JM, Bird SR, Ibrahim N, Fling SP, Homet Moreno B, Sharon E, Cheever MA, Topalian SL.

J Clin Oncol. 2019 Mar 20;37(9):693-702. doi: 10.1200/JCO.18.01896. Epub 2019 Feb 6.

PMID:
30726175
4.

Updates in adjuvant systemic therapy for melanoma.

Kwak M, Farrow NE, Salama AKS, Mosca PJ, Hanks BA, Slingluff CL, Beasley GM.

J Surg Oncol. 2019 Jan;119(2):222-231. doi: 10.1002/jso.25298. Epub 2018 Nov 27. Review.

PMID:
30481375
5.

Stromal Fibroblasts Mediate Anti-PD-1 Resistance via MMP-9 and Dictate TGFβ Inhibitor Sequencing in Melanoma.

Zhao F, Evans K, Xiao C, DeVito N, Theivanthiran B, Holtzhausen A, Siska PJ, Blobe GC, Hanks BA.

Cancer Immunol Res. 2018 Dec;6(12):1459-1471. doi: 10.1158/2326-6066.CIR-18-0086. Epub 2018 Sep 12.

6.

Paracrine Wnt5a-β-Catenin Signaling Triggers a Metabolic Program that Drives Dendritic Cell Tolerization.

Zhao F, Xiao C, Evans KS, Theivanthiran T, DeVito N, Holtzhausen A, Liu J, Liu X, Boczkowski D, Nair S, Locasale JW, Hanks BA.

Immunity. 2018 Jan 16;48(1):147-160.e7. doi: 10.1016/j.immuni.2017.12.004.

7.

Identifying baseline immune-related biomarkers to predict clinical outcome of immunotherapy.

Gnjatic S, Bronte V, Brunet LR, Butler MO, Disis ML, Galon J, Hakansson LG, Hanks BA, Karanikas V, Khleif SN, Kirkwood JM, Miller LD, Schendel DJ, Tanneau I, Wigginton JM, Butterfield LH.

J Immunother Cancer. 2017 May 16;5:44. doi: 10.1186/s40425-017-0243-4. eCollection 2017. Review.

8.

Genetic risk analysis of a patient with fulminant autoimmune type 1 diabetes mellitus secondary to combination ipilimumab and nivolumab immunotherapy.

Lowe JR, Perry DJ, Salama AK, Mathews CE, Moss LG, Hanks BA.

J Immunother Cancer. 2016 Dec 20;4:89. doi: 10.1186/s40425-016-0196-z. eCollection 2016.

9.

Safety and Efficacy of Radiation Therapy in Advanced Melanoma Patients Treated With Ipilimumab.

Qin R, Olson A, Singh B, Thomas S, Wolf S, Bhavsar NA, Hanks BA, Salama JK, Salama AK.

Int J Radiat Oncol Biol Phys. 2016 Sep 1;96(1):72-7. doi: 10.1016/j.ijrobp.2016.04.017. Epub 2016 Apr 21.

PMID:
27375168
10.
11.

Isolated recto-sigmoid colitis: a new imaging pattern of ipilimumab-associated colitis.

Barina AR, Bashir MR, Howard BA, Hanks BA, Salama AK, Jaffe TA.

Abdom Radiol (NY). 2016 Feb;41(2):207-14. doi: 10.1007/s00261-015-0560-3.

PMID:
26867901
12.

Melanoma-Derived Wnt5a Promotes Local Dendritic-Cell Expression of IDO and Immunotolerance: Opportunities for Pharmacologic Enhancement of Immunotherapy.

Holtzhausen A, Zhao F, Evans KS, Tsutsui M, Orabona C, Tyler DS, Hanks BA.

Cancer Immunol Res. 2015 Sep;3(9):1082-95. doi: 10.1158/2326-6066.CIR-14-0167. Epub 2015 Jun 3.

13.

Rapid complete response of metastatic melanoma in a patient undergoing ipilimumab immunotherapy in the setting of active ulcerative colitis.

Bostwick AD, Salama AK, Hanks BA.

J Immunother Cancer. 2015 May 19;3:19. doi: 10.1186/s40425-015-0064-2. eCollection 2015.

14.
15.

Type III TGF-β receptor downregulation generates an immunotolerant tumor microenvironment.

Hanks BA, Holtzhausen A, Evans KS, Jamieson R, Gimpel P, Campbell OM, Hector-Greene M, Sun L, Tewari A, George A, Starr M, Nixon A, Augustine C, Beasley G, Tyler DS, Osada T, Morse MA, Ling L, Lyerly HK, Blobe GC.

J Clin Invest. 2013 Sep;123(9):3925-40. doi: 10.1172/JCI65745. Epub 2013 Aug 8.

16.

Improved time to progression for transarterial chemoembolization compared with transarterial embolization for patients with unresectable hepatocellular carcinoma.

Morse MA, Hanks BA, Suhocki P, Doan PL, Liu EA, Frost P, Bernard SA, Tsai A, Moore DT, O'Neil BH.

Clin Colorectal Cancer. 2012 Sep;11(3):185-90. doi: 10.1016/j.clcc.2011.11.003. Epub 2012 Jan 26.

PMID:
22280845
17.

Pharmacological inhibition of TGFβ as a strategy to augment the antitumor immune response.

Hanks BA, Morse MA.

Curr Opin Investig Drugs. 2010 Dec;11(12):1342-53. Review.

PMID:
21154116
18.

Enhanced activation of human dendritic cells by inducible CD40 and Toll-like receptor-4 ligation.

Lapteva N, Seethammagari MR, Hanks BA, Jiang J, Levitt JM, Slawin KM, Spencer DM.

Cancer Res. 2007 Nov 1;67(21):10528-37.

19.

Re-engineered CD40 receptor enables potent pharmacological activation of dendritic-cell cancer vaccines in vivo.

Hanks BA, Jiang J, Singh RA, Song W, Barry M, Huls MH, Slawin KM, Spencer DM.

Nat Med. 2005 Feb;11(2):130-7. Epub 2005 Jan 23.

PMID:
15665830
20.

Template-based docking of a prolactin receptor proline-rich motif octapeptide to FKBP12: implications for cytokine receptor signaling.

Soman KV, Hanks BA, Tien H, Chari MV, O'Neal KD, Morrisett JD.

Protein Sci. 1997 May;6(5):999-1008.

21.

Comparison of the functional differences for the homologous residues within the carboxy phosphate and carbamate domains of carbamoyl phosphate synthetase.

Javid-Majd F, Stapleton MA, Harmon MF, Hanks BA, Mullins LS, Raushel FM.

Biochemistry. 1996 Nov 12;35(45):14362-9.

PMID:
8916923
22.

Role of conserved residues within the carboxy phosphate domain of carbamoyl phosphate synthetase.

Stapleton MA, Javid-Majd F, Harmon MF, Hanks BA, Grahmann JL, Mullins LS, Raushel FM.

Biochemistry. 1996 Nov 12;35(45):14352-61.

PMID:
8916922

Supplemental Content

Loading ...
Support Center